Lapatinib (GW-572016) Ditosylate

• CAT Number: A000336
• CAS Number: 388082-77-7
• Molecular Formula: C29H26ClFN4O4S.2C7H8O3S
• Molecular Weight: 925.46
• Purity: ≥95%
• Target: Protein Tyrosine Kinase/RTK
• Storage: -20 ℃
• IUPAC Name: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;4-methylbenzenesulfonic acid
• InChI: 1S/C29H26ClFN4O4S.2C7H8O3S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19;2*1-6-2-4-7(5-3-6)11(8,9)10/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35);2*2-5H,1H3,(H,8,9,10)
• InChIKey: UWYXLGUQQFPJRI-UHFFFAOYSA-N
• SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

Lapatinib (GW-572016) Ditosylate is a potent, dual epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor used in cancer treatment. It selectively blocks signaling pathways involved in tumor growth and proliferation, particularly in HER2-positive breast cancer. The ditosylate salt form enhances the drug’s solubility and bioavailability. Lapatinib is crucial in targeting resistant breast cancer strains, often used in combination with other therapies to improve clinical outcomes.